New England Journal of Medicine publishes phase III data showing Xolair (omalizumab) significantly reduced allergic reactions across multiple foods in people With food allergies – Genentech/Roche
Genentech, a member of the Roche Group, announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and… read more.